MHC class II allosteric site drugs: New immunotherapeutics for malignant, infectious and autoimmune diseases

Scandinavian Journal of Immunology

Volumn 54, Issue 1-2, 2001, Pages 39-44

  Xu, M ^a   Li, J ^a   Gulfo, J V ^a   Von Hofe, E ^a   Humphreys, R E ^a  

^a Antigen Express Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; CYTOKINE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNTHETIC PEPTIDE;

ACTIVE IMMUNIZATION; ALLOSTERISM; ANTIGEN BINDING; AUTOIMMUNE DISEASE; BINDING SITE; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; REVIEW;

ALLOSTERIC SITE; ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PEPTIDES;

EID: 0034950193     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2001.00964.x     Document Type: Review

References (43)

1. Proteolysis and class I major histocompatibility complex antigen presentation
2. The nature of the MHC class I peptide loading complex
3. The MHC class II-associated invariant chain: A molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells
4. Genetic modulation of tumor antigen presentation
5. MHC Class II-associated invariant chain contains a sorting signal for endosomal compartments
6. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes
7. Role for intracellular proteases in the processing and transport of class II HLA antigens
8. Inhibition by leupeptin and antipain of the intracellular proteolysis of Ii
9. Cathepsin B cleavage and release of invariant chain from MHC Class II molecules follow a staged pattern
10. Charging of peptides to MHC class II molecules during proteolysis of Ii
11. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size
12. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides
13. Mapping functional regions in the lumenal domain of the class II-associated invariant chain
14. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy
15. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules
16. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading
17. Quality control of MHC class II associated peptides by HLA-DM/H2-M
18. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules
19. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC Class II molecules
20. Immunosupression and antigen supercharging by Ii-Key peptide-related compounds - A new class of drugs controlling the first step in antigen recognition
21. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1
22. From epitopes to peptides to immunotherapy
23. Human tumor antigens for cancer vaccine development
24. The discovery and use of HLA-associated epitopes as drugs
25. Dominance and crypticity of T cell antigenic determinants
26. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
27. Quantitative analysis of peptide-MHC class II interaction
28. MHC ligands and peptide motifs: First listing
29. The structure of an intermediate in class II MHC maturation. CLIP bound to HLA-DR3
30. Increasing the potency of MHC Class II-presented epitopes by linkage to Ii-Key peptide
31. A peptide binding weakly to the major histocompatibility molecule augments T cell responses
32. An accessory peptide binding site with allosteric effect on the formation of peptide-MHC-II complexes?
33. Kinetics of antigenic peptide binding to the class II major histocompatibility molecule I-Ad
34. Enhancement of peptide antigen presentation by a second peptide
35. Kinetics and specificity of peptide-MHC Class II complex displacement reactions
36. Selective release of some invariant chain-derived peptides from HLA-DR, 1 molecules at endosomal pH
37. Self-release of CLIP in peptide loading of HLA-DR molecules
38. Interaction of MHC Class II molecules with the invariant chain: Role of the invariant chain (81-90) region
39. Autoimmune recognition of MHC Class II. Insights into augmenting immunogenicity of nominal peptides
40. N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively
41. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
42. Proliferative and cytokine responses to class II HER-2/neu associated peptides in breast cancer
43. 96